Background: Early postnatal antibiotic use has been shown to pro-
Introduction
Antibiotics are the most commonly prescribed pharmacologic agents during pregnancy (1) , despite insufficient evidence to support their use in preventing adverse effects on pregnancy outcomes (2) . In addition to perturbing the maternal microbiome (3), a potentially unintended consequence of using antibiotics in pregnancy is the trans-placental effect of antibiotics on the foetus (4) .
While the intrauterine environment had been considered sterile (5) , the recently discovered presence of bacterial DNA in the placenta (6) , umbilical cord blood (7) and foetal membranes (8) from healthy pregnancies suggests maternal-foetal transfer of microbiota before birth. A mother-to-foetus transfer of bacteria may facilitate development of not only the naïve foetal immune system (5) but also metabolic systems and growth (9) . Antibiotics taken by pregnant women, which enter foetal circulation via the placenta (4), may disrupt a mother-to-foetus bacterial transfer and, in doing so, alter foetal growth and body composition, much like antibiotics are believed to do when taken during infancy (10) and childhood (11) .
Yet whether prenatal antibiotic use is associated with foetal growth and adiposity is unclear. While observational studies suggest that the use of antibiotics in the third trimester in pregnancy is associated with higher birth weight (12, 13) , a more recent report indicated that use of antibiotics earlier in pregnancy was associated with lower birth weight (14) . Clinical trials have also been mixed, with many showing that antibiotic treatment increases birth weight (15) (16) (17) (18) (19) (20) but others reporting a null effect (21) (22) (23) . The discrepancy in findings may be due to inconsistency in the outcomes used (birth weight vs. birth weight for gestational age), and timing, duration, dose and nature (chemical class) of the antibiotic exposure. Furthermore, no studies have examined prenatal antibiotics in relation to adipokines levels as reflection of foetal adiposity. Leptin and adiponectin are adipokines that regulate energy homeostasis and metabolism (24) , and higher levels of leptin and adiponectin in cord blood correlate with greater neonatal body fat stores (25) . Moreover, cord blood leptin levels have been associated with body weight status at age 3 (26), suggesting that the perinatal leptin has a programming role in weight regulation in early childhood.
In the present analysis of a large cohort of women and their offspring, our aim was to examine overall and trimester-specific antibiotic use in relation to birth weight for gestational age and cord blood leptin and adiponectin levels.
Methods

Subjects
Project Viva is a pre-birth cohort study of prenatal and perinatal exposures, pregnancy outcomes and offspring health. We recruited 2341 eligible women in their first prenatal visit at Atrius Harvard Vanguard Medical Associates, a multispecialty group practice in eastern Massachusetts. Details of participant recruitment and study protocol have been reported (27) . For the current study, we included 2128 (91% of total) Project Viva participants with a live singleton birth and data available concerning prenatal antibiotics. Among these participants, 2127 had data for birth weight, and 839 also had data available for cord blood leptin and 880 for adiponectin. Mothers provided written informed consent at enrollment and for their infants after birth, and the Institutional Review Boards of the participating sites approved the study.
Measures
Exposures -assessment of prenatal antibiotics
We extracted prescription data from the electronic medical records of the group practice to derive overall and trimester-specific oral antibiotic use (full list of oral antibiotics available in Table S1 ). We defined first trimester antibiotics as those prescribed between the last menstrual period and 91 d of gestation, second trimester antibiotics as those prescribed 92-182 d of pregnancy and third trimester antibiotics as those prescribed >182 d of pregnancy to delivery date.
Outcomes -assessment of foetal growth and umbilical cord leptin and adiponectin
We obtained infant birth weight in grams (g) and date of delivery from the hospital medical record. We calculated sex-specific birth weight-for-gestational-age z-score from a US national reference as previously described (28) . We collected cord blood samples from the umbilical vein immediately after delivery of the infant, refrigerated whole blood for <24 h, then spun and aliquoted samples for storage in liquid nitrogen (À80°C). We measured concentrations of leptin and adiponectin in cord blood with a radioimmunoassay (Linco Research Inc., St Charles, MO, USA).
Covariates -assessment of participant characteristics
Through interviews and questionnaires, we collected information on mothers' age, race/ethnicity, education, household income, smoking habits and date of last menstrual period. For the 237 of 2128 (11%) mother-infant pairs where gestational age according to the second trimester ultrasound differed from that according to the last menstrual period by >10 d, we used the ultrasound result to determine gestational duration. We calculated mothers' pre-pregnancy body mass index (BMI; kg m
À2
) from self-reported weight (kg) and height (m). We calculated total gestational weight gain as the difference between self-reported pre-pregnancy weight and the last clinical weight recorded before delivery.
Data analysis
We used linear regression to evaluate associations of overall and trimester-specific prenatal antibiotic prescription with birth weight-for-gestational-age z-score as our primary outcome and with cord blood leptin and adiponectin levels as our secondary outcomes.
All outcomes were normally distributed. For our trimester-specific analysis, we excluded individuals who were prescribed with antibiotics in a trimester previous to the index trimester to avoid confounding. In sensitivity analyses, we examined the trimester exposures as prescribed antibiotics vs. not prescribed antibiotics in each trimester without exclusions. As additional sensitivity analysis, we examined prescribed antibiotics in each trimester vs. not prescribed antibiotics at any point in pregnancy.
To assess confounding, we began with an unadjusted model and then created a multivariable model that included maternal age (continuous), pre-pregnancy BMI (continuous), parity (nulliparous vs. multiparous), race/ethnicity (White, Black, Asian, Hispanic and other), education (has at least a college degree vs some college or less), smoking habits (smoked during pregnancy, formerly smoked and never smoked) and household income (>$70 000 per year vs. less) and child sex. We additionally adjusted cord blood leptin and adiponectin models for gestation length. We considered but did not include in the final model gestational weight gain, pre-pregnancy physical activity and diet during pregnancy, because the estimate for each primary exposure changed by <10%, which did not meet a standard confounder definition (29) .
We evaluated effect modification on the multiplicative scale by including cross-product terms for trimester-specific antibiotic use and sex in multivariable models, considering p < 0.05 as evidence of interaction. Analyses were performed using SAS 9.3 (SAS Institute, Cary, NC, USA).t
Results
Antibiotic prescriptions overall and by trimester can be found in Table S1 . In total, there were 1150 total oral antibiotic prescriptions during pregnancy in this cohort. The majority of the prescriptions were for penicillins (39.0%), but nitrofurantoin, metronidazole and macrolides each accounted for more than 14%. Penicillins were more likely to be prescribed in the third trimester, whereas metronidazole was more likely to be prescribed in the second trimester.
Of the 2128 women included in the final analytic set, 643 (or 30.2%) women were prescribed with antibiotics at some point during pregnancy. More than half (n = 358; 56%) of women prescribed with antibiotics received a single prescription, but 285 (44%) received more than or equal to two prescriptions (Table S2 ). Baseline characteristics for mother-infant dyads are shown in ), were less likely to be college educated (53.7% vs. 69.4%) and were more likely to be Black or Hispanic and to smoke in pregnancy (16.8% vs. 10.8%). In the overall cohort, mean (standard deviation) birth weight-for-gestational-age z-score was 0.17 (0.97), cord blood leptin was 9.0 (6.6) and cord blood adiponectin was 28.8 (6.8). Table 2 shows unadjusted and multivariable adjusted associations of prenatal antibiotics with birth weight-forgestational-age z-scores. Any prescription of prenatal antibiotics was associated with smaller birth weightfor-gestational-age z-scores before [β À0.09; 95% confidence interval {CI}: À0.18, 0.00] and after (β À0.11; 95% CI: À0.20, À0.01) multivariable adjustment. The association appeared to differ qualitatively according to the trimester in which antibiotics were prescribed. In trimester-specific analyses, second trimester antibiotic prescription was associated with lower birth weight-for-gestational-age z-score (β À0.23; 95% CI À0.37, À0.08). First trimester prescription also tended towards an inverse association (À0.09; 95% CI À0.21, 0.04) but with apparent smaller effect size than second trimester exposure. In contrast, third trimester antibiotic prescription tended to be associated with greater birth weight-for-gestational-age z-score, but this did not reach statistical significance (β 0.07; 95% CI À0.11, 0.25). There was no evidence of a doseresponse between number of antibiotic prescriptions and birth weight-for-gestational-age z-scores, in overall or trimester-specific analyses (Table S3) .
In Table 3 , we present associations of antibiotics with cord blood leptin and adiponectin levels. Overall, prescription of antibiotics in pregnancy was not associated with levels of leptin or adiponectin in cord blood. However, associations varied by the trimester in which antibiotics were prescribed. We observed that third trimester antibiotic prescription was associated with higher cord leptin (adjusted β 2.28; 95% CI: 0.38, 4.17) in line with the direction of effect expected from birth weight-for-gestational-age z-score analyses. Moreover, there was evidence that the number of antibiotic prescriptions in third trimester was positively associated with leptin levels in a dose-dependent fashion (compared with 0 prescriptions, adjusted β 1.67; 95% CI: À0.37, 3.71 for one prescription and adjusted β 5.72; 95% CI: 1.05, 10.39 for more than or equal to two prescriptions; Table  S3 ). Results for adiponectin trended in the same direction but did not reach statistical significance.
Our overall findings did not vary appreciably when we used 'not prescribed antibiotics in each trimester without exclusions' or 'not prescribed antibiotics at any point in pregnancy' as reference groups for our Prenatal antibiotics and foetal growth | 131 trimester-specific antibiotic analyses (Tables S4 and  S5 ). We also did not find evidence for multiplicative effect modification by sex on the associations for overall or trimester-specific antibiotics with birth weight-for-gestational-age z-scores (p-values >0.20).
Discussion
In this pre-birth cohort study, we found that prescription of oral antibiotics in pregnancy was associated with foetal growth and cord blood leptin. Overall, prenatal antibiotic prescriptions were associated with BMI, body mass index; BW/GA-z, birth weight-for-gestational-age z-score; SD, standard deviation.
lower birth weight-for-gestational-age z-scores. Antibiotics prescribed early in pregnancy, during the first but mostly the second trimester, drove this inverse association. However, in babies of women who were prescribed with antibiotics during the third trimester, there was a tendency towards higher birth weightfor-gestational-age z-scores, and third trimester antibiotics were associated with higher levels of cord blood leptin, a marker of foetal adiposity (25) . Previous observational studies and clinical trials have been inconsistent about the direction of the association between antibiotic use in pregnancy and foetal growth. That inconsistency may be due, at least in part, to the differential timing of antibiotic use during gestation. Our finding that antibiotics prescribed earlier in pregnancy (in the second trimester and to a lesser extent first trimester) are associated with lower birth weight-for-gestational-age z-scores is consistent with an observational study of 397 women in the Southeastern USA, which found that self-reported antibiotic usage between 8 weeks preconception and 20 weeks gestation was associated with 138 g lower birth weight, after adjusting for confounding factors including gestational age (14) . Yet, randomized controlled clinical trials of erythromycin vs. placebo (n = 324) (22) and metronidazole plus cephalexin vs. placebo (n = 240) (21) , initiated in the second trimester of pregnancy with the aim of improving birth outcomes, showed that antibiotic treatment had no effect on birth weight or gestational length. Other clinical trials in the USA studying metronidazole between 16-24 weeks gestation (n = 953) (30) and metronidazole plus erythromycin between 21-25 weeks gestation (n = 703) (31) for the prevention of preterm birth reported that antibiotic treatment did not prevent low (<2500 g) birth weight, but these findings are not directly comparable with ours as the authors did not examine the relation to birth weight Adjusted for maternal age, pre-pregnancy BMI, parity, race/ethnicity, education, smoking habits, household income, and child sex and gestation length. *Among 839 women for leptin analyses and 880 women for adiponectin analyses. **Among 730 women (for leptin analyses) and 763 women (for adiponectin analyses) who were not prescribed with antibiotics in the first trimester. ***Among 653 women (for leptin analyses) and 682 women (for adiponectin analyses) who were not prescribed with antibiotics in the first or second trimester.
for gestational age as a continuous variable. The inverse association between early pregnancy antibiotics and foetal growth observed in observational studies, but not clinical trials, raises the hypothesis that underlying infections for which the antibiotics were prescribed may be driving the observed association.
On the other hand, most observational studies (12, 13) and clinical trials (15) (16) (17) (18) (19) (20) , but not all (21) (22) (23) , converge on the finding that antibiotics used later in pregnancy have a positive association with foetal growth. McCormack et al. randomized 1071 US women between 22 and 32 weeks gestation to receive erythromycin, clindamycin or placebo to determine whether antibiotic treatment prevents low birth weight. They found that while treatment with clindamycin and erythromycin initiated during the second trimester of pregnancy had no effect on birth weight, treatment with erythromycin during the third trimester of pregnancy increased mean birth weight by 144 g (17) . This trial did not report on whether antibiotic treatment affected gestational age. Moreover, two randomized, double blind, placebocontrolled trials in Kenya, conducted to explore the potential benefits of routine antimicrobial therapy, found that compared with women who received a placebo, those who received a single dose of either intramuscular ceftriaxone (n = 400) (15) or oral cefetamet pivoxil (n = 320) (16) between 28 and 32 weeks gestation delivered babies with 153 and 155 g greater birth weight, respectively, despite the antibiotic treatments not having an effect on gestational length. Of note, none of the aforementioned trials examined birth weight for gestational age as an outcome and all of the clinical trials cited earlier were conducted in pregnancies at high risk for preterm birth or low birth weight, whereas our observational study was conducted in a generally healthy population.
Our finding that antibiotics prescribed in the third trimester had a positive association with cord blood leptin levels, despite not having an association with birth weight for gestational age, suggests that antibiotics in the third trimester might affect foetal adiposity, because cord blood leptin levels have been positively correlated with neonatal percent body fat at birth (25, 32) . Our observations may also be the effect of antibiotics on placenta, because placental tissues express and release leptin on both maternal and foetal sides (33) We also observed a parallel but nonsignificant association between third trimester antibiotics and cord blood adiponectin levels. Adiponectin also positively correlates with foetal fat stores (25) . That third trimester antibiotic prescriptions were associated with levels of leptin and adiponectin in a dose-response fashion (Table S2) is consistent with these associations having true biologic underpinnings. Future research is warranted to replicate these adipokine findings and to determine whether they have long-term metabolic implications for the newborn.
Several limitations to our study are worth noting. First, in our study, it was not possible to separate infection from antibiotic treatment as the two are linked, and we had no data on untreated prenatal infections. We do not know whether the infection for which the antibiotic was prescribed influenced foetal growth and adiposity. Yet one would expect that while infections during pregnancy have been associated with preterm birth in other studies (34), we did not find any association between antibiotic prescriptions and gestational age in our study. Another limitation is possible exposure misclassification by use of prescription data from medical records, as treatment adherence was not studied. Finally, as this is an observational study, we cannot rule out unmeasured or residual confounding.
Strengths of our study include the comprehensive set of covariates to control for many potential confounders and the information on specific type of antibiotics and their date of prescription. Moreover, unlike previous studies on this topic, our study largely eliminated confounding by gestational age through use of gestational age-specific birth weights.
In conclusion, prenatal antibiotic prescription was associated with altered foetal growth measures, but the direction of the associations depended on the trimester in which the antibiotics were prescribed. Prescriptions in mid-pregnancy were associated with lower birth weight for gestational age, yet prescriptions in the third trimester were associated with higher cord blood leptin. One possibility is that two separate phenomena are at play: early prescriptions may reflect the deleterious consequences of early infections, for which the antibiotics were intended to treat, whereas antibiotics prescribed late in pregnancy may affect the interplay of the maternal microbiome with foetal development. These hypotheses will require further testing.
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